MedTrace Logo

Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

NCT05309187 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2024-06-04

No results posted yet for this study

Summary

To assess safety and tolerability of increasing doses of IO-202 either as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors, and select the recommended Phase 2 dose (RP2D).

Conditions

  • Solid Tumor, Adult

Interventions

BIOLOGICAL

IO-202

IO-202 given as monotherapy

BIOLOGICAL

IO-202 + pembrolizumab combination therapy

IO-202 and fixed dose pembrolizumab combination therapy

BIOLOGICAL

RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types

Expansion cohorts of the RP2D of IO-202 and fixed dose pembrolizumab combination therapy in multiple tumor types.

Sponsors & Collaborators

  • Immune-Onc Therapeutics

    lead INDUSTRY

Principal Investigators

  • Roya Nawabi, MBA · Immune-Onc Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-11
Primary Completion
2024-03-29
Completion
2024-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05309187 on ClinicalTrials.gov